Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
In the new movie "Contagion," fictional health experts scramble to get ahead of a flu-like pandemic as a drug-resistant virus quickly spreads, killing millions of people within days after they contract the illness.
Hollywood's latest thriller “Contagion” seems to have captured the public’s interest with strong sales at the box office. In the movie tens of millions of people are wiped out by the rapid spread of a killer airborne disease. It's a scenario real-life experts say is entirely plausible.
Nobody likes to get stuck with a needle. But influenza - the flu - is particularly hazardous for those with neuromuscular disease, which is why the Muscular Dystrophy Association (MDA) and Walgreens have teamed up once again to offer free seasonal flu shots now underway for people who have muscular dystrophy and related diseases.
Nexera Medical, Inc., today announced plans to submit to the U.S. Food and Drug Administration amended antimicrobial claims for its current 510(k) clearance for the SpectraShield 9500 Surgical N95 Respirator with embedded antimicrobial technology. The expanded antimicrobial claims will be supported by test data on the inactivation performance of certain strains of viruses.
NanoViricides, Inc. announced today that it has selected a clinical candidate, now designated NV-INF-1, for FDA submission in its highly successful FluCide anti-influenza therapeutics program.
The Pennsylvania departments of Health and Agriculture today announced three cases of a novel influenza A virus have been identified, and are now linked to an agricultural fair in southwestern Pennsylvania.
Northwestern University professor Dirk Brockmann and his group at the McCormick School of Engineering and Applied Science have investigated the outcomes of a previously ignored mechanism in modeling how humans travel.
"Finland's national health institute said on Thursday its latest research on previously found links between children's narcolepsy and GlaxoSmithKline's Pandemrix vaccine against H1N1 swine flu also involved a genetic risk factor," Reuters reports.
The influenza pandemic has gathered a lot of action, advice and coverage over the last few years. In 2009, an international H1N1 influenza pandemic led to concerns that there would be a repeat of the 1918 influenza pandemic which resulted in millions of deaths worldwide. The World Health Organization recorded over 37,000 cases of the H1N1 pandemic influenza in Australia and 193 confirmed deaths.
A new study of children's hospitals nationwide has found them underequipped to handle a major surge of patients in the event of a pandemic, and urges health care institutions and government agencies to immediately review emergency preparedness plans as flu season approaches.
IQuum, Inc. announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market the Liat Influenza A/B Assay and the Liat Analyzer.
New research shows that the occurrence of narcolepsy in China is highly correlated to a seasonal pattern, with onset most frequent in April.
The onset of narcolepsy appears to follow seasonal patterns of H1N1 and other upper airway infections, according to a new study of patients in China that was led by Stanford University School of Medicine narcolepsy expert Emmanuel Mignot, MD.
When the influenza A (H1N1) virus swept around the world in spring 2009, infection was presumed to be more common in immunosuppressed patients, such as those who have had a kidney transplant. Later that year, the International Societies of Transplantation recommended that transplant recipients receive at least one dose of the H1N1 vaccine, although there was no information on the efficacy of the vaccine in that population.
According to a new survey despite recent improvements in influenza vaccination rates among U.S. health care personnel, their rates for the 2010-2011 flu season still fell short of national health objectives.
CEL-SCI Corporation today announced that the Chinese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine.
The last century has seen two major pandemics caused by the H1N1 virus - the Spanish Flu in 1918 and 2009's Swine Flu scare, which had thousands travelling with surgical masks and clamoring for vaccination. But scientists did not know what distinguished the Swine Flu from ordinary influenza in pigs or seasonal outbreaks in humans, giving it the power to travel extensively and infect large populations.
In a new development that could transform how viral infections are treated, a team of researchers at MIT’s Lincoln Laboratory has designed a drug that can identify cells that have been infected by any type of virus, then kill those cells to terminate the infection.
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter financial results for the period ended June 30, 2011.
"The World Health Organization is declaring an end to the global swine flu pandemic," the Associated Press/Seattle Times reports.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.